β-Secretase1 biological markers for Alzheimer’s disease: state-of-art of validation and qualification

β-Secretase1 biological markers for Alzheimer’s disease: state-of-art of validation and qualification

Abstract β-Secretase1 (BACE1) protein concentrations and rates of enzyme activity, analyzed in human bodily fluids, are promising candidate biological markers for guidance in clinical trials investigating BACE1 inhibitors to halt or delay the dysregulation of the amyloid-β pathway in Alzheimer’s dis...

Full description

Bibliographic Details
Main Authors: Harald Hampel, Simone Lista, Eugeen Vanmechelen, Henrik Zetterberg, Filippo Sean Giorgi, Alessandro Galgani, Kaj Blennow, Filippo Caraci, Brati Das, Riqiang Yan, Andrea Vergallo, for the Alzheimer’s Precision Medicine Initiative (APMI)
Format: Article
Language:English
Published: BMC 2020-10-01
Series:Alzheimer’s Research & Therapy
Subjects:
Alzheimer’s disease
Amyloid-β pathway
Axonal damage
BACE1
Clinical trials
Context of use
Online Access:http://link.springer.com/article/10.1186/s13195-020-00686-3

Internet

http://link.springer.com/article/10.1186/s13195-020-00686-3

Similar Items